Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2013 October;61(5) > Minerva Cardioangiologica 2013 October;61(5):563-74

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

REVIEWS  


Minerva Cardioangiologica 2013 October;61(5):563-74

language: English

Biodegradable-polymer-based drug-eluting stent for left main coronary artery disease

Gutiérrez-Chico J. L., Jochheim D., Mehilli J.

Department of Cardiology Munich University Clinic, Munich, Germany


PDF  


Percutaneous coronary interventions (PCI) have gained widespread acceptation among cardiologists and among the general population for a variety of clinical indications, comprising from stable angina to ST-elevation acute myocardial infarction, due to the undisputed clinical benefit they provide and to their large availability and accessibility. Nonetheless PCI in the left main coronary artery (LMCA) is still controversial. Traditionally the revascularization of the LMCA has been one of those exceptions in which surgery was preferred to PCI, although PCI still found a slot in non-surgically-suitable cases or as bailout intervention. Some evidence has been recently generated, that challenges this traditional approach, and also about the clinical advantages of new-generation intracoronary devices, among them the drug-eluting stents with biodegradable polymers in abluminal coating. This scenario opens new horizons for the treatment of LMCA disease, in which a more prominent role of PCI can be anticipated.

top of page

Publication History

Cite this article as

Corresponding author e-mail

Julinda.Mehilli@med.uni-muenchen.de